Rani Therapeutics (RANI) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

48NeutralDD: Jun 12, 2026Analyst: 59

paidPrice at analysis date

USD 0.82 (12/06/2026)

domainMkt cap

$92M

pie_chartShares

9.49

candlestick_chart52W

$0.39-$3.87

trending_downShort interest

9.49%

MEDIUMNASDAQHealth Care70 employeesFounded 2012

Verdict: Moderately Attractive —

High-asymmetry binary platform play. RaniPill HC oral delivery validated by $1.085B Chugai deal (Oct 2025); RT-114 oral GLP-1 obesity in Phase 1. Cash floor $0.39/sh, runway into Q4 2027. BUT: active Nasdaq minimum bid non-compliance (deadline 2026-11-09), CFO resigning, micro-cap liquidity. Setup is a survivable lottery ticket — cash floor protects ~50% of price; bull case is 3-5x on partnership flow or platform M&A.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-12

Rani Therapeutics (RANI)

Clinical-stage biotech · Oral drug delivery · San Jose, CA

"Binary platform optionality with cash floor and partnership validation, offset by active Nasdaq non-compliance"

Chugai $1.085B opt Cash floor $0.39 RT-114 obesity Ph1 Nasdaq delisting risk CFO resigning

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV (Cash floor + Chugai deal NPV + Pipeline option value)

Fair value base case

USD 0.80

Range: USD 0.30-USD 4.50

Price at analysis date: USD 0.82 (12/06/2026)

Base upside/downside: -2%

Methodology: Risk-adjusted NPV / sum-of-the-parts. Cash floor (hard) + Chugai deal probability-weighted by milestone tranche + RT-114 option-valued pre-Phase 1 + other pipeline aggregated + 5Y operating burn − expected dilution. Modal base case $0.80 vs probability-weighted expectation $1.34 — divergence reflects long-right-tail asymmetry typical of clinical-stage platform plays. Implied EV/cash 1.12x is at the distressed end of clinical biotech peers. Main sensitivity: RT-114 success probability (±10pts = ±$0.18). ⚠️ Not investment advice.

Component	Assumption	USD/share
Cash floor (hard anchor)	$43.4M cash & ST investments / 112.4M shares; zero LT debt	+0.39
Chugai deal — risk-adj. NPV	$18M tech transfer × 60% + $57M dev × 20% + $100M sales × 5% + 4 option targets × $10M × 15% = $33.4M / 112.4M	+0.30
RT-114 obesity (oral GLP-1) option	30% prob Phase 1 read-out validates platform × $200M expected partnership value = $60M / 112.4M	+0.53
RT-111 immunology + RT-116 + other	20% prob × $50M aggregate platform deal value = $10M / 112.4M	+0.09
Operating losses to break-even (rNPV)	~$32M cumulative net of Chugai cash inflow over 5Y to break-even / 112.4M	−0.30
Anticipated dilution (1-2 raises)	Estimated ~30% additional dilution before profitability × FV impact	−0.21
FV base case	Sum: 0.39 + 0.30 + 0.53 + 0.09 − 0.30 − 0.21	≈ $0.80

Bull

$2.50–$5.00

Probability: 25%

RT-114 obesity Phase 1 shows weight loss + tolerability. Triggers partnership at $300M+ total value or strategic acquirer interest (Lilly, Novo, AstraZeneca). Chugai exercises 2+ option targets. Nasdaq compliance achieved via natural price recovery. Re-rate to GPCR/AQST-tier multiples.

Base

$0.50–$1.00

Probability: 40%

RT-114 generates mixed/early data, ongoing development. Chugai milestones flow slowly. 1-for-10 reverse split executed to maintain listing. 1-2 additional capital raises before profitability. Platform value gradually rebuilds.

Bear

$0.20–$0.40

Probability: 35%

RT-114 fails Phase 1 / safety signal. Nasdaq delisting to OTC. Chugai cancels option exercises. Forced dilutive financing at distressed terms. Stock drifts toward residual cash value, eventual orderly wind-down or sale of IP.

Methodology: Methodology: Risk-adjusted NPV / sum-of-the-parts. Cash floor (hard) + Chugai deal probability-weighted by milestone tranche + RT-114 option-valued pre-Phase 1 + other pipeline aggregated + 5Y operating burn − expected dilution. Modal base case $0.80 vs probability-weighted expectation $1.34 — divergence reflects long-right-tail asymmetry typical of clinical-stage platform plays. Implied EV/cash 1.12x is at the distressed end of clinical biotech peers. Main sensitivity: RT-114 success probability (±10pts = ±$0.18). ⚠️ Not investment advice. Not investment advice.

warning

🚨 Active Nasdaq Minimum Bid Non-Compliance

May 11, 2026 — RANI received Nasdaq notice that closing bid has been below $1.00 for 30 consecutive trading days. Deadline to cure: November 9, 2026 (180 days) by achieving close ≥$1.00 for 10 consecutive business days. Possible 180-day extension via Nasdaq Capital Market transfer. Reverse split is the practical fallback (typically 1-for-5 to 1-for-15) which preserves listing but does not change underlying value. Compounding governance signal: CFO Svai Sanford resigning post-successor with 9-month severance + accelerated vesting.

check_circle

✅ Founder/Director Insider Buying at Depressed Levels

Founder, Director and 10% owner Mir A. Imran purchased 2,083,334 shares of Class A common stock at $0.605 in the October 2025 PIPE (~$1.26M cash outlay) — strong skin-in-the-game signal from the founder buying alongside the Chugai deal announcement, at prices below the current market.

⚠️ Methodology note: Pre-revenue clinical-stage biotech micro-cap. Standard EBITDA/DCF inapplicable. Fair value built via risk-adjusted NPV (rNPV) of pipeline + Chugai deal + cash floor. Cash floor ($0.39/sh) is the hard downside anchor; upside is binary on clinical readouts and partnership flow.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

9.5%

9.47M shares short on 112.39M outstanding. Days to cover ~3-5d. Moderate level — market hedging delisting risk and clinical binary, but no squeeze setup.

🔴 Share dilution (1Y)

+85% est.

From ~61M to 112.4M shares. Driver: October 2025 PIPE ($60.3M raised at $0.605, founder Imran participating). Further dilution expected before profitability.

🔴 Buyback

N/A — pre-revenue clinical-stage, cash conservation priority. Capital allocation = R&D + clinical execution exclusively.

Short Interest — context

RANI — 9.5%

9.5%

9.5% SI is moderate for a micro-cap biotech with active Nasdaq non-compliance and binary clinical catalysts — relatively benign considering setup. Insider buying note: Founder/Director Mir Imran purchased 2.08M shares at $0.605 in Oct 2025 PIPE (~$1.26M cash). Multiple Form 4 filings show director option grants but no concentrated insider selling — meaningful positive signal vs typical micro-cap biotech distress pattern.

$Financial analysis — FY 2025 & Q1 FY 2026

Cash & ST investments

$43.4M

47% of market cap

Q1'26 net loss

−$8.0M

vs −$12.7M YoY (−37%)

Runway

Q4 2027

~6 quarters (incl. Chugai milestone)

LT debt

Debt-free

Item ($M)	FY2023	FY2024	FY2025	Q1 FY2026	FY2026 outlook
Contract revenue	0.4	0.6	3.5	1.7	~6–8 (Chugai)
R&D expense	50.1	45.2	28.0	6.5	~28
G&A expense	22.5	20.1	16.0	3.5	~15
Operating loss	−72.2	−64.7	−40.5	−8.3	~−37
Net loss	−68.0	−58.2	−38.8	−8.0	~−35
Cash & ST inv (EOP)	52.5	30.2	51.0	43.4	~22 (pre Chugai milestone)
Shares outstanding (M)	30.5	54.2	112.4	112.4	—

Note: FY25 figures restated — operating loss reduced 37% YoY via cost discipline + pipeline reprioritization. FY24/FY23 R&D higher reflecting endocrinology programs since deprioritized. Shares jumped from 54M to 112M in Oct 2025 PIPE.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	0.2	0.4	0.5	2.4	1.7
Operating loss ($M)	−12.7	−11.5	−10.0	−9.3	−8.3
R&D expense ($M)	8.5	7.5	6.5	5.5	6.5
Net loss ($M)	−12.7	−11.0	−9.5	−5.6	−8.0
End-of-period cash ($M)	22.0	14.0	68.0	51.0	43.4

Financial position and sustainability

Cash runway (quarters)

~6 (Q4'27)

Operating loss YoY reduction

−37%

Nasdaq cure window remaining

150 of 180 days

Cash / Market cap

47%

account_tree

Business model — Oral biotherapeutic delivery platform

RaniPill HC: turning injectable biologics into pills

Rani's core IP is the RaniPill HC capsule — a small ingestible device that bypasses the stomach and delivers monoclonal antibodies, GLP-1 peptides and other biologics directly to the intestinal wall via micro-needle. Preclinical data showed 107-111% relative bioavailability vs subcutaneous injection of semaglutide and a dual GLP-1/GLP-2 agonist. The thesis: if validated clinically, oral delivery transforms patient adherence and economics across $50B+ injectable biologic markets (obesity, immunology, rare disease). The business has pivoted from doing its own clinical work to a platform-licensing model: Chugai (Oct 2025) and ProGen (RT-114) are the proof points.

Obesity / GLP-1 (RT-114, RT-116) Phase 1 active (RT-114) 🟢 advancing RT-114 = ProGen's dual GLP-1/GLP-2 agonist PG-102 in RaniPill capsule. Phase 1 study in Australia comparing oral vs SC. Wegovy market $3.1B/half; total injectable GLP-1 market $50B+ by 2030. Highest-value asset. Chugai partnership (hemophilia) $10M upfront + up to $1.085B 🟢 active Oct 2025 deal: Chugai antibody for hemophilia in RaniPill HC. $10M upfront, up to $175M in dev/sales milestones per target, single-digit royalties, option to add 5 targets. Validation by major Roche affiliate. Immunology + rare disease (RT-111, others) Preclinical / partnered 🟡 to prove Anti-TNF and other immunology candidates. Lower-priority endocrinology programs paused. Focus on partnering rather than internal development.

gavel

Legal, regulatory and risk analysis

Nasdaq minimum bid non-compliance

Critical

Active notice (May 11, 2026). Deadline Nov 9, 2026 to close ≥$1.00 for 10 consecutive days. Reverse split likely backstop (typically 1:5 to 1:10). Does not change underlying value but enables continued listing.

Clinical binary risk — RT-114 Phase 1

High

Phase 1 readout will be platform-defining: success validates RaniPill HC across multiple biologics, partnership flood; failure (safety signal, missed PK targets) collapses platform thesis. Outcome largely binary.

Going-concern / runway tightness

Moderate

Runway "into Q4 2027" assumes Chugai milestone payment. Slip would shorten window. Likely 1-2 additional financings before partnership-driven sustainability. Each raise = further dilution at distressed multiples.

CFO resignation / governance turnover

Moderate

CFO Svai Sanford resigning with 9-month severance + accelerated vesting. CFO departures during compliance crises are negative signals; new CFO will need to navigate Nasdaq cure and financing simultaneously.

GLP-1 competitive overhang

High

Multiple oral GLP-1 small molecules in development (Lilly orforglipron, Pfizer danuglipron, Structure GPCR0177). If small-molecule oral wins, RaniPill HC route becomes redundant for obesity. Defense = device works for antibodies, not just GLP-1.

Cash floor $0.39/sh + zero debt

Positive

$43.4M cash + ST inv with no LT debt = $0.39/sh hard floor. Provides ~50% downside protection from current price. Survivable even in distress scenarios via IP sale.

Chugai $1.085B platform validation

Positive

Chugai (Roche affiliate, ~$25B mkt cap) signed $10M upfront + up to $1.085B with option for 5 additional targets. Independent validation of RaniPill HC by top-tier biopharma — significantly de-risks platform credibility.

Founder insider buying signal

Positive

Founder/Director Mir Imran bought 2.08M shares at $0.605 in Oct 2025 PIPE (~$1.26M cash). Founder participation in financing at distressed levels = strong skin-in-the-game vs typical micro-cap pattern.

article

SWOT analysis

Strengths

+RaniPill HC platform with 107-111% bioavailability vs SC — unmatched among oral biologic delivery
+Chugai $1.085B deal (Oct 2025) = independent top-tier validation
+$43.4M cash, zero LT debt, founder buying — micro-cap by survival metrics
+Cost discipline: operating loss down 37% YoY; runway extended into Q4 2027
+Phase 1 RT-114 ongoing — material near-term catalyst

Weaknesses

−Pre-revenue platform, contract revenue only $1.7M Q1'26
−Active Nasdaq minimum bid non-compliance, listing at risk
−Heavy dilution: shares 30M → 112M in 3 years (+265%)
−Micro-cap liquidity ($92M mkt cap), institutional ownership limited
−CFO resignation amid compliance crisis

Opportunities

→Oral GLP-1 obesity market $50B+ by 2030 (Wegovy alone $3.1B/half)
→Chugai option targets (5) — each = $10M upfront + $175M milestones potential
→Platform M&A: Lilly, Novo, AstraZeneca, BMS as potential acquirers if RT-114 validates
→Immunology biologics ($100B+ aggregate market) addressable via RaniPill HC
→Reverse split + capital return narrative could re-rate if executed cleanly

Threats

!Oral small-molecule GLP-1s (orforglipron, danuglipron) bypass device need for obesity
!RT-114 Phase 1 failure = thesis-ending event (platform credibility collapses)
!Forced distressed financing at sub-$0.50 = continued dilution spiral
!Delisting to OTC = institutional unmarketable, further loss of liquidity

article

Summary by assessment area

🔴 Compliance/Governance Risk — Critical

Active Nasdaq notice, Nov 9 deadline
CFO resigning amid crisis
Reverse split likely backstop
Delisting = institutional unmarketable

🟡 Clinical/Execution Risk — High but bounded

RT-114 Phase 1 read-out = binary platform event
Chugai validation de-risks platform credibility
Cash runway ~6 quarters tight but adequate
Founder buying signals conviction

🔵 Valuation Risk — Asymmetric

FV $0.80 vs price $0.82 → essentially fair
Bull $2.50-$5.00 (25%) / Bear $0.20-$0.40 (35%)
EV/Cash 1.12x = distressed end of peers
Cash floor $0.39 limits downside to ~50%

2026-09-30product

RT-114 Phase 1 obesity interim PK/safety data

medium-termImpact: HighDirection: Binary

Most consequential catalyst. Validates (or invalidates) RaniPill HC for oral GLP-1 delivery. Success = platform-defining, opens partnership flood for obesity TAM. Failure = thesis collapse, fall to cash floor.

2026-11-09regulatory

Nasdaq minimum bid cure deadline (or reverse split)

medium-termImpact: HighDirection: Binary

Need close ≥$1.00 for 10 consecutive days. If not achieved organically by Nov 9, reverse split (1:5 to 1:10) is the practical path. Possible 180-day extension via Capital Market transfer.

2026-12-31partnership

Chugai technology transfer milestone (up to $18M)

medium-termImpact: HighDirection: Bullish

Tech transfer milestone payment baked into runway guidance. Slip = runway tightening, possible accelerated dilutive raise. Hit = runway confirmation + partnership credibility.

2026-08-13earnings

Q2 FY26 Earnings Release

short-termImpact: MediumDirection: Neutral

Watch: cash burn trajectory, Chugai milestone timing commentary, RT-114 enrollment update, CFO successor announcement. Catalyst weight modest; main signal = Nasdaq cure plan.

2027-01-31partnership

Possible Chugai option target nomination

long-termImpact: MediumDirection: Bullish

Chugai holds option for 5 additional targets. Each nomination = $10M upfront + up to $175M milestones. First option exercise would meaningfully re-rate platform value perception.

2027-06-30product

RT-114 Phase 1 topline (weight loss + PK)

long-termImpact: HighDirection: Binary

Full topline establishes platform-grade evidence. Positive readout = strategic acquirer interest, partnership at $300M+ value plausible. Negative readout = down to cash floor.

2027-03-31capital_markets

Likely additional capital raise window

long-termImpact: MediumDirection: Bearish

Approximately 6 months before runway expiration. Form S-3 shelf already filed. Terms depend on RT-114 data & Chugai milestone status. Best case: clean PIPE post-data; worst case: distressed equity raise.

{ "verdict_label": {"it": "Moderatamente Attraente", "en": "Moderately Attractive"}, "verdict_text": {"it": "Platform play binario ad alta asimmetria. RaniPill HC validato da deal Chugai $1.085B. RT-114 obesità in Fase 1. Cassa floor $0.39, runway Q4 2027. MA: Nasdaq compliance attiva, CFO uscente. Bull 3-5x, bear sul floor cassa.", "en": "High-asymmetry binary platform play. RaniPill HC validated by Chugai $1.085B deal. RT-114 obesity in Phase 1. Cash floor $0.39, runway Q4 2027. BUT: active Nasdaq non-compliance, CFO exiting. Bull 3-5x, bear to cash floor."}, "bull_points": [ {"it": "Deal Chugai $1.085B + opzione su 5 target = validazione platform da affiliata Roche", "en": "Chugai $1.085B + 5 option targets = top-tier biopharma platform validation"}, {"it": "RT-114 GLP-1 orale: TAM obesità $50B+ entro 2030 (Wegovy $3.1B/semestre)", "en": "RT-114 oral GLP-1: $50B+ obesity TAM by 2030 (Wegovy $3.1B/half)"}, {"it": "EV/Cassa 1.12x = mercato sconta il platform a zero, founder Imran ha comprato a $0.605", "en": "EV/Cash 1.12x = market discounts platform to zero, founder Imran bought at $0.605"} ], "bear_points": [ {"it": "Nasdaq minimum bid non-compliance attiva, deadline 9 nov 2026, reverse split probabile", "en": "Active Nasdaq minimum bid non-compliance, Nov 9, 2026 deadline, reverse split likely"}, {"it": "RT-114 Phase 1 binario: fallimento = collasso tesi platform e ritorno al floor cassa", "en": "RT-114 Phase 1 binary: failure = platform thesis collapse, return to cash floor"}, {"it": "Diluizione storica pesante (30M → 112M azioni in 3 anni), altre raise probabili", "en": "Heavy historical dilution (30M → 112M shares in 3 years), more raises likely"} ], "risks": [ {"it": "GLP-1 orali small-molecule (orforglipron, danuglipron) potrebbero bypassare la necessità del device", "en": "Oral small-molecule GLP-1s (orforglipron, danuglipron) could bypass the device need"}, {"it": "Delisting a OTC = perdita liquidità istituzionale, accesso al capitale compromesso", "en": "Delisting to OTC = loss of institutional liquidity, capital access impaired"}, {"it": "CFO Sanford dimissionario in piena crisi compliance: segnale di governance debole", "en": "CFO Sanford resigning amid compliance crisis: weak governance signal"} ] }

Sources & Disclaimer

Sources: SEC EDGAR (Rani 10-K FY2025, 10-Q Q1 FY2026, 8-K Nasdaq notice May 11 2026, Form 4 insider transactions Oct 2025, Form S-3 shelf), Rani IR press releases (Chugai collaboration Oct 17 2025, RT-114 Phase 1 initiation, Q1 2026 results), GlobeNewswire, StockTitan, Yahoo Finance, StockAnalysis.com, Fintel.io, CNN Markets, MarketBeat, Simply Wall St, TipRanks. Market data — last verified close 2026-06-08: RANI ~$0.82–$0.84, market cap ~$92M, 52W range: $0.39–$3.87, 112.39M Class A shares outstanding. Short interest: 9.49% (9.47M shares). Founder Mir Imran bought 2.08M shares at $0.605 in Oct 2025 PIPE. Nasdaq minimum bid non-compliance active since May 11, 2026, cure deadline Nov 9, 2026. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.